

Table 1: Characteristics of included studies

Study	Patients	Intervention		Comparison		Outcomes of interest reported	Follow-up
		Type	Characteristics	Type	Characteristics		
<i>Kleinstäuber, 2014</i>							
Aragona, 2005 <i>RCT, Italy</i>	Adult patients with pain disorder according to DSM-IV-TR criteria	Citalopram <i>Mean dose: 40 mg/day, max dose: 40 mg/day, 1 tablet twice daily</i>	n = 15 Mean age (SD): 56 (14) years Male (%): 27	Reboxetine <i>Mean dose: 8 mg/day, max dose: 8 mg/day, 1 tablet twice daily</i>	n = 14 Mean age (SD): 51 (18) years Male (%): 29	Psychological complaints Adverse events	Treatment duration: 56 days
Han, 2008a <i>RCT, Korea</i>	Adult patients with undifferentiated somatoform disorder based on DSM-IV criteria	Mirtazapine <i>Mean dose: 31.7 mg/day, max dose: 60 mg/day</i>	n = 28 Mean age (SD): 46 (13) years Male (%): 40	Venlafaxine <i>Mean dose: 105.5 mg/day, max dose: 225 mg/day</i>	n = 17 Mean age (SD): 45 (12) years Male (%): 38	Physical complaints Psychological complaints Adverse events	Treatment duration: 84 days
Han, 2008b <i>RCT, Korea</i>	Adult patients with undifferentiated somatoform disorder based on DSM-IV criteria	Fluoxetine <i>Mean dose: 36.1 mg/day, max dose: 60 mg/day</i>	n = 50 Mean age (SD): 38 (13) years Male (%): 43	Sertraline <i>Mean dose: 167.7 mg/day, max dose: 350 mg/day</i>	n = 45 Mean age (SD): 38 (10) years Male (%): 41	Physical complaints Psychological complaints Adverse events	Treatment duration: 84 days
Muller, 2008 <i>RCT, South Africa</i>	Patients with undifferentiated somatoform disorder according to DSM-IV or ICD-10	Escitalopram Mean dose: 14.4 mg/day, max dose: 20 mg/day	n = 25 Mean age (SD): 38 (10) years Male (%): 12	Placebo	n = 26 Mean age (SD): 42 (9) years Male (%): 8	Physical complaints Functioning Psychological complaints Adverse events	Treatment duration: 84 days